Uncategorized
Apellis’ geographic atrophy treatment meets phase 2 endpoint
A phase 2 study of Apellis Pharmaceuticals’ APL-2 for geographic atrophy in age-related macular degeneration has met its primary endpoint at 12 months, according to a company press release.APL-2 injected intravitreally monthly in the multicenter, randomized, single-masked FILLY trial statistically significantly reduced the rate of geographic atrophy lesion growth 29% compared with sham (P = .008). Every-other-month administration reduced the rate 20% (P = .067), the release said.